Provepharm will participate for the first time in the National Training Days on medical devices organized by Euro-pharmat, which will be held in La Rochelle from October 4 to 6, 2022.
For the third consecutive year, Provepharm will participate in the "Convergences Santé Hôpital" Meetings, which will take place from September 13 to 16, 2022 at the Neptune Convention Center in Toulon.
Our CSR report, published for seven years on the Global Compact website, has become an essential medium for promoting our voluntary and ambitious approach to all of our stakeholders.
Provepharm receives FDA approval for BLUDIGO™ (indigotindisulfonate sodium, USP) Injection
Act to improve life.
Act is the commitment tomobilize our resources to achieve our mission.
Act is daring to refuse the status quo and to define new standards of innovation.
Provepharm will participate in the HOPIPHARM Francophone Congress of Hospital Pharmacy, which will take place from 18 to 20 May 2022 at the Lille Congress Center.
Our CSR approach expands a little more each year and remains a central element of our strategy. To manage it effectively, it was necessary to equip ourselves with a tool to measure, improve and communicate our CSR actions.